uniQure to Announce Second Quarter 2025 Financial Results
uniQure (NASDAQ: QURE), a leading gene therapy company, will release its second quarter 2025 financial results before market open on Tuesday, July 29, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
uniQure (NASDAQ: QURE), a leading gene therapy company, will release its second quarter 2025 financial results before market open on Tuesday, July 29, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results.
The earnings call will be accessible via webcast through uniQure's website under the Events & Presentations section, with a replay available for 90 days. Phone participants must pre-register online to receive dial-in details and are advised to join 15 minutes before the start time.
Details
News Market Reaction – QURE
The recorded move for QURE in the trading session of this news was -1.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET
LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before market open on Tuesday, July 29, 2025. Management will then host a conference call at 8:30 a.m. ET.
The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. If you are joining the conference call, please dial in 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Contacts:
| FOR INVESTORS: Chiara Russo Direct: 781-491-4371 Mobile: 617-306-9137 c.russo@uniQure.com | FOR MEDIA: Tom Malone Direct: 339-970-7558 Mobile:339-223-8541 t.malone@uniQure.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.